openPR Logo
Press release

Diffusive Alveolar Hemorrhage Treatment Market Booming with Immunotherapy, Growing at 6.6% CAGR (2024-2031) | Top Companies 2025 - F. Hoffmann-La Roche Ltd, Cadila Pharmaceuticals.,

07-11-2025 07:13 AM CET | Health & Medicine

Press release from: DataM intelligence 4 Market Research LLP

Diffusive Alveolar Hemorrhage Treatment Market

Diffusive Alveolar Hemorrhage Treatment Market

The Global Diffusive Alveolar Hemorrhage Treatment Market reached US$ 562 million in 2023 and is expected to reach US$ 926 million by 2031, growing at a CAGR of 6.6% during the forecast period 2024-2031.

The Diffusive Alveolar Hemorrhage Treatment Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. By combining qualitative and quantitative research methodologies, the firm delivers in-depth reports that help clients navigate complex market dynamics, drive strategic growth, and seize new opportunities in an ever-evolving global landscape.

Download your exclusive free sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/diffusive-alveolar-hemorrhage-treatment-market?sp

Diffusive Alveolar Hemorrhage Treatment Market Landscape Analysis :

Diffuse alveolar hemorrhage (DAH) is a rare, life-threatening condition characterized by bleeding into the alveolar spaces of the lungs, leading to respiratory distress and impaired oxygen exchange. Treatment typically involves a combination of corticosteroids, immunosuppressive therapies, and supportive care, depending on the underlying cause such as autoimmune disease, infection, or drug toxicity.

Diffusive Alveolar Hemorrhage Treatment Market Dynamics:

The increasing prevalence of autoimmune diseases like systemic lupus erythematosus (SLE) and systemic vasculitis is a key driver for the growth of the diffusive alveolar hemorrhage (DAH) treatment market. Improved diagnostics are expanding the identified patient pool, boosting demand for targeted therapies. As per the Annals of Rheumatic Disease (2022), the global incidence of SLE is 5.14 per 100,000, translating to over 413,000 cases in 2023. With DAH affecting up to 5.4% of SLE patients, the number of DAH cases linked to autoimmune diseases is steadily rising. Broader causes like infections and cardiac conditions further contribute to market expansion.

Diffusive Alveolar Hemorrhage Treatment Market: Recent Industry Developments

✅A recent report from an HSCT center described a combined inhaled/intrabronchial protocol using rFVIIa and TXA that achieved a 100% initial hemostasis rate in five pediatric transplant patients, with no procedural complications

✅Avacopan approved in 2024 for antineutrophil cytoplasmic antibody-associated vasculitis (AAV).

Strategic Players Driving the Diffusive Alveolar Hemorrhage Treatment Market Forward:
F. Hoffmann-La Roche Ltd, Cadila Pharmaceuticals., Teva Pharmaceuticals USA, Inc., Amgen Inc., Baxter., Pfizer Inc., GSK plc, Horizon Therapeutics plc, Sandoz AG, and Sun Pharmaceutical Industries Ltd. among others.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/diffusive-alveolar-hemorrhage-treatment-market?sp

Research Methodology:
The global Diffusive Alveolar Hemorrhage Treatment Market research report employs a comprehensive dual-source approach, integrating both primary and secondary data collection methods to ensure robust market analysis. Our research framework systematically evaluates multiple industry-influencing variables, including regulatory frameworks and government policies, prevailing market conditions, competitive intensity levels, historical performance data, current market positioning, technological innovations and disruptions, emerging industry developments, cross-sector business impacts, market volatility patterns, growth prospects, potential market barriers, and strategic challenges facing industry participants.

Segment Covered in the Diffusive Alveolar Hemorrhage Treatment Market:

➠By Type: Autoimmune Induced Alveolar Hemorrhage, Drug-Induced Alveolar
Hemorrhage, Infection Induced Alveolar Hemorrhage, Others

➠By Treatment Type: Pharmacotherapy, Plasma Exchange Therapy, Supportive Care

➠By Patient Type: Pediatrics, Adults, Geriatrics

Regional Analysis for Diffusive Alveolar Hemorrhage Treatment Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=diffusive-alveolar-hemorrhage-treatment-market?sp

Most Frequently Asked Questions in the Diffusive Alveolar Hemorrhage Treatment Market Research Industry:
➠ Who leads the Diffusive Alveolar Hemorrhage Treatment industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Diffusive Alveolar Hemorrhage Treatment market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Diffusive Alveolar Hemorrhage Treatment market growth?
➠ What are the dominant sales and distribution strategies in the Diffusive Alveolar Hemorrhage Treatment industry?

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diffusive Alveolar Hemorrhage Treatment Market Booming with Immunotherapy, Growing at 6.6% CAGR (2024-2031) | Top Companies 2025 - F. Hoffmann-La Roche Ltd, Cadila Pharmaceuticals., here

News-ID: 4100326 • Views:

More Releases from DataM intelligence 4 Market Research LLP

USA Medium Chain Triglycerides Market Accelerates - Valued at USD 871.21 Million in 2025, On Track to Reach USD 1,296.03 Million by 2032
USA Medium Chain Triglycerides Market Accelerates - Valued at USD 871.21 Million …
DataM Intelligence announces the release of its market report, "Medium Chain Triglycerides Market: Size, Share, Trends & Forecast 2025-2032." According to the analysis, the Medium Chain Triglycerides Market (MCT Market) in the USA is valued at USD 871.21 million in 2025. It is projected to grow at a CAGR of 5.09%, reaching USD 1,296.03 million by 2032. The increase in consumer demand for clean-label, energy-boosting, and functional food ingredients is
United States Autoimmune Treatment Market 2025 | Growth Drivers, Key Players & Investment Opportunities
United States Autoimmune Treatment Market 2025 | Growth Drivers, Key Players & I …
Market Size and Growth The Global Autoimmune Treatment Market is predicted to reach at a Significant CAGR during the forecast period (2024-2031) Key Development: United States: Recent Industry Developments ✅ October 6, 2025 - Mary Brunkow and Fred Ramsdell (USA) and Shimon Sakaguchi (Japan) were awarded the Nobel Prize in Physiology or Medicine for their pioneering research on regulatory T cells and the FOXP3 gene, laying the groundwork for over 200 clinical trials
United States Atherosclerosis Drugs Market 2025 | Growth Drivers, Key Players & Investment Opportunities
United States Atherosclerosis Drugs Market 2025 | Growth Drivers, Key Players & …
Market Size and Growth Global Atherosclerosis Drugs Market reached US$ 26.4 billion in 2023 and is expected to reach US$ 32.5 billion by 2031 growing with a CAGR of 2.6% during the forecast period 2024-2031. Key Development: United States: Recent Industry Developments ✅ In October 2025, Amgen announced a significant move by offering its cholesterol-lowering drug, Repatha, directly to U.S. consumers at a 60% discount, pricing it at $239 per month. This initiative aims
United States G-Protein Coupled Receptor (GPCR) Targeting Market 2025 | Growth Drivers, Key Players & Investment Opportunities
United States G-Protein Coupled Receptor (GPCR) Targeting Market 2025 | Growth D …
Market Size and Growth G-protein Coupled Receptor (GPCR) Targeting Market is Expected to reach at a high CAGR of 6.40% during the forecast period (2024-2031). Key Development: United States: Recent Developments in GPCR Targeting ✅ In August 2025, Nxera Pharma announced the launch of an expanded drug discovery pipeline targeting obesity and related metabolic diseases. The company is focusing on a range of validated GPCR targets, building on existing collaborations with Pfizer and

All 5 Releases


More Releases for Alveolar

Autoimmune Pulmonary Alveolar Proteinosis Market Massive Growth opportunity Ahea …
Introduction Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare lung disorder characterized by the accumulation of surfactant in the alveoli, impairing oxygen exchange and causing progressive respiratory symptoms. The disease arises due to autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF), which block the clearance of surfactant by alveolar macrophages. For decades, the gold standard of treatment has been whole lung lavage (WLL)-a labor-intensive, invasive procedure requiring specialized centers. While effective in reducing symptoms,
Pulmonary Alveolar Proteinosis Drug Market Size, Analyzing Trends and Projected …
The Pulmonary Alveolar Proteinosis Market Is Set To Grow At An Estimated CAGR Of 6.0% From 2025 To 2034, Rising From $800 Million In 2024 To $1.4 Billion By 2034. On April 29, 2025, Exactitude Consultancy., Ltd. released a research report titled "Pulmonary Alveolar Proteinosis Drug Market" This report offers a new perspective on the Pulmonary Alveolar Proteinosis Drug Market covering an extensive range of aspects including market overview, expenditure analysis,
Pulmonary Alveolar Proteinosis (PAP) Market Driven by Demand for Immersive Techn …
Global Pulmonary Alveolar Proteinosis (PAP) Market Impact of AI and Automation The Pulmonary Alveolar Proteinosis (PAP) market is witnessing significant growth as awareness of this rare lung disease increases and medical research advances. PAP is characterized by the accumulation of surfactant in the lungs, impairing gas exchange and leading to respiratory issues. The growing recognition of PAP's symptoms and its impact on patients' quality of life has led to increased diagnosis
Alveolar Polypropylene Packing Market Size,Volume,Revenue Trends Analysis Report …
Global Info Research announces the release of the report "Global Alveolar Polypropylene Packing Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029" . The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets.
Alveolar Soft Part Sarcoma Market - Unleashing Progress: Alveolar Soft Part Sarc …
Newark, New Castle, USA: The "Alveolar Soft Part Sarcoma Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors. Alveolar Soft Part Sarcoma Market: https://www.growthplusreports.com/report/alveolar-soft-part-sarcoma-market/8620 This latest report researches the
Autoimmune Pulmonary Alveolar Proteinosis Market to Witness Growth by 2032 | Est …
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Autoimmune Pulmonary Alveolar Proteinosis, historical and forecasted epidemiology as well as the Autoimmune Pulmonary Alveolar Proteinosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Autoimmune Pulmonary Alveolar Proteinosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and